Clinical trials: Sitagliptin, completed
Non-alcoholic Fatty Liver Disease
Sitagliptin Versus Placebo in the Treatment of Non-alcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of diseases ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), the progressive form of liver disease that can lead to cirrhosis and liver-related…
- Trial name
- NCT01963845
- Testing
- Sitagliptin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Diego
Type 2 Diabetes Mellitus
Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy Subjects
To assess the effect of glimepiride on the PK of dapagliflozin and the effect of dapagliflozin on the PK of glimepiride, when co-administered in healthy subjects (Phase A) and to assess the effect of sitagliptin on the PK of…
- Trial name
- NCT00842556
- Testing
- Dapagliflozin, Glimepiride, Sitagliptin
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
The purpose of this study is to evaluate benefits and risks of lixisenatide (AVE0010), in comparison to sitagliptin, as an add-on treatment to metformin, in obese (body mass index [BMI] greater than or equal to 30 kilogram per…
- Trial name
- NCT00976937
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Sitagliptin
- Where
- 92 sites in United States, Australia and 11 more
- Volunteers
- 319 people
- Sponsor
- Sanofi
Leukemia, Myeloid, Acute, Acute Lymphoblastic Leukemia
Sitagliptin Umbilical Cord Blood Transplant Study
The main purpose of this trial is to study whether the drug sitagliptin can be given safely to patients undergoing umbilical cord blood transplantation to speed up engraftment (recovery of blood counts after transplant).
- Conditions
- Leukemia, Myeloid, Acute, Acute Lymphoblastic Leukemia, Myelodysplasia, Leukemia, Myelogenous, Chronic
- Trial name
- NCT00862719
- Testing
- Sitagliptin
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Indiana University
Type 2 Diabetes Mellitus
Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine
Primary Objective: To demonstrate significant reduction in postprandial plasma glucose (ΔAUC0:30-4:30h) after a standardized breakfast from baseline to Day 29.
- Trial name
- NCT02200991
- Testing
- LIXISENATIDE AVE0010, Sitagliptin, Insulin glargine HOE901
- Where
- 20 sites in Japan
- Volunteers
- 136 people
- Sponsor
- Sanofi
Type 2 Diabetes, Hyperlipidemia
Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin
A 16 week open-label study with subjects receiving background metformin monotherapy. 150 subjects randomized 1:1:1 to receive 1 of the following: open-label colesevelam HCl, open label rosiglitazone, or open-label sitagliptin.
- Trial name
- NCT00484419
- Testing
- Colesevelam HCl, rosiglitazone maleate, sitagliptin phosphate
- Where
- 20 sites in United States
- Volunteers
- 169 people
- Sponsor
- Daiichi Sankyo
Type 2 Diabetes Mellitus
Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes
Study B1621019 will assess efficacy and safety of two different dosing regimens of an investigational agent (PF-04937319) compared to an approved drug (sitagliptin) in patients with type 2 diabetes
- Trial name
- NCT01933672
- Testing
- PF-04937319 once-daily, PF-04937319 split-dose, Sitagliptin once-daily
- Where
- 8 sites in United States
- Volunteers
- 33 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2
An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024)
The purpose of this investigational study is to determine the safety and effectiveness of an investigational drug in patients with type 2 diabetes mellitus (a specific type of diabetes).
- Trial name
- NCT00094770
- Testing
- sitagliptin (MK0431), Comparator: glipizide
- Volunteers
- 1,172 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 1 Diabetes
Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus
To study the effects of GLP 1 analogues and DPP 4 inhibitors on newly detected type 1 diabetes patients.
- Trial name
- NCT01235819
- Testing
- Insulin, Sitagliptin, Exenatide
- Where
- India
- Volunteers
- 20 people
- Sponsor
- Command Hospital, India
Diabetes Mellitus, Type II
CKD-396 Drug-drug Interaction Study(A) (CKD-396 DDI(A) P1)
The purpose of this study is to evaluate a pharmacokinetic drug interaction between lobeglitazone and sitagliptin in healthy male volunteers.
- Trial name
- NCT02824874
- Testing
- Duvie Tab. 0.5mg, Duvie Tab. 0.5mg + Januvia Tab. 100mg
- Where
- South Korea
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Diabetes Mellitus
Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to determine the efficacy and safety of SYR-472, once daily (QD), in subjects with type 2 diabetes mellitus who have not achieved glycemic control with diet and exercise, or by taking metformin.
- Trial name
- NCT00760344
- Testing
- SYR-472, Sitagliptin
- Where
- 112 sites in United States, Mexico
- Volunteers
- 386 people
- Sponsor
- Takeda
Severe Obesity
Influence of Gut Hormones on Food Intake After Roux-en-Y Gastric Bypass Surgery
The aim of this study is to examine the effect of GLP-1 and other gut-secreted hormones (glucagon, GIP, grelin and PYY) on food-intake, appetite and glucose metabolism after Roux-en-Y gastric bypass surgery.
- Trial name
- NCT02336659
- Testing
- exendin 9-39, sitagliptin
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- Hvidovre University Hospital
Cystic Fibrosis
Treatment of Dysglycemia Using Sitagliptin in Adolescents With Cystic Fibrosis
This pilot study will be conducted in adolescents with cystic fibrosis (CF) without diabetes but with abnormal glucose tolerance, and will assess the effects of sitagliptin on glucose regulation.
- Trial name
- NCT01721382
- Testing
- Sitagliptin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Nemours Children's Clinic
Type 2 Diabetes
A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes
Phase 3 study to compare treatment with ITCA 650 to sitagliptin when added to metformin monotherapy in patients with type 2 diabetes.
- Trial name
- NCT01455870
- Testing
- ITCA 650 60 mcg/day, sitagliptin
- Where
- 54 sites in United States, Croatia and 3 more
- Volunteers
- 535 people
- Sponsor
- Intarcia Therapeutics
Type 2 Diabetes Mellitus (T2DM)
Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus
A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic (blood sugar) control on metformin therapy.
- Trial name
- NCT00337610
- Testing
- sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day
- Volunteers
- 190 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
Feed-Back Suppression of Meal-Induced Glucagon-like Peptide 1 (GLP-1) Secretion
The present study is a phase I, single-centre, double-blind, randomized, cross-over (3 treatments, 3 treatment periods and 6 sequences), stratified (background medication: metformin vs.
- Trial name
- NCT02749032
- Testing
- Mixed meal test, Vildagliptin, Sitagliptin
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Michael A. Nauck
Type 2 Diabetes Mellitus
Incretin-based Drugs and the Risk of Heart Failure
The purpose of this study is to determine whether incretin-based drugs (used to treat type 2 diabetes) taken either alone or in combination with other anti-diabetic drugs are associated with an increased risk of heart failure…
- Trial name
- NCT02456428
- Testing
- DPP-4 inhibitors, GLP-1 analogs, Insulins
- Where
- Canada
- Volunteers
- 1,499,650 people
- Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
Type 2 Diabetes Mellitus
Sitagliptin and Kinetics of Triglyceride-rich Lipoproteins Apolipoprotein B48 and B100 in Patients With Type 2 Diabetes
Sitagliptin is a potent and selective inhibitor of dipeptidyl peptidase IV (DPP-IV), and has been shown to reduce fasting and postprandial glucose levels in patients with type 2 diabetes mainly through incretin hormone-mediated…
- Trial name
- JANUB48 (NCT01334229)
- Testing
- Sitagliptin
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- Laval University
Diabetes Mellitus, Type 2
Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus
The purpose of this study is to determine the efficacy and safety of TAK-875, once daily (QD), in combination with sitagliptin QD in participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01414920
- Testing
- TAK-875, Sitagliptin, TAK-875 and Sitagliptin
- Where
- 80 sites in United States
- Volunteers
- 368 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2
Incretin-based Drugs and Pancreatic Cancer
The purpose of this study is to determine whether incretin-based drugs (used to treat type 2 diabetes) taken either alone in or combination with other anti-diabetic drugs are associated with an increased risk of pancreatic cancer…
- Trial name
- NCT02475499
- Testing
- DPP-4 inhibitors, GLP-1 analogs, Sulfonylureas
- Where
- Canada
- Volunteers
- 886,172 people
- Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES